Global specialist law firm Dechert LLP has been ranked among the top law firms for biotech and pharma licensing agreements by BioPharm Insight in its 2015 year-end licensing league table rankings.
Dechert was ranked as a leading law firm for both total value and total volume of biotech and pharma licensing agreements in all of the 2015 categories, including: Asia-Pacific, Europe, North America and globally – demonstrating the strength of Dechert’s cross-border platform for life sciences companies.
“This recognition is a testament to our continued leadership in both domestic and cross-border licensing transactions,” said David Schulman, co-chair of the firm’s life sciences practice. “Our global team of life sciences lawyers remain committed to understanding the business opportunities and challenges of our clients and providing them with real-world solutions.”
Licensing highlights from 2015 include representing:
- Celgene Corporation, a global biopharmaceutical company, in the acquisition of a 10% stake in Juno Therapeutics, Inc. as part of a 10-year collaboration for the development and commercialization of immunotherapies worth approximately US$1 billion. Winner of LMG Life Sciences “Collaboration Deal of the Year” award.
- uniQure N.V. on an agreement with Bristol-Myers Squibb Company that provides Bristol-Myers Squibb Company with exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases.
- Egalet US, Inc. and Egalet Ltd in a collaboration and license agreement with Acura Pharmaceuticals, Inc. pursuant to which Egalet obtained exclusive worldwide rights to commercialize Acura's immediate release oxycodone hydrochloride product which incorporates Acura’s patented Aversion® (abuse-deterrent) Technology platform.
- Johnson & Johnson Innovation – JJDC, Inc. (Johnson & Johnson’s corporate strategic investment arm) and its affiliate Ethicon Endo-Surgery, Inc. in connection with J&J’s entry into transaction agreements with Google regarding the formation and governance of a collaboration to innovate robotic surgical technologies. Winner of LMG Life Sciences “Collaboration Deal of the Year” award.
- Resverlogix Corp. on an equity investment and a license of RVX-208 to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau.
- Celgene Corporation, a global biopharmaceutical company, through its subsidiary Celgene International II Sàrl, in its strategic collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC, to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies for an upfront payment of US$450 million.
- 4SC AG, a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, in its licensing and development partnership with Singapore-based company Menarini Asia-Pacific Holdings Pte. Ltd. focused on 4SC’s cancer compound resminostat for the Asia-Pacific region excluding Japan.
About Dechert
Dechert is a global specialist law firm with a deep bench of experts focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients’ most important matters. Nothing stands in the way of giving clients the best of the firm’s entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.
Related Professionals
